(Q30668465)

26 June 2017

title

The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy (English)

1 reference

26 June 2017

1 reference

0 references

Patrick L McGeer

1

1 reference

26 June 2017

Edith G McGeer

series ordinal

2

1 reference

26 June 2017

publication date

20 September 2013

1 reference

26 June 2017

published in

Acta Neuropathologica

1 reference

26 June 2017

volume

126

1 reference

26 June 2017

issue

4

1 reference

26 June 2017

page(s)

479-497

1 reference

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Randomized pilot study of nimesulide treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of beta-amyloid protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Vitamin D, cognition, and dementia: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Amyloid-beta dynamics correlate with neurological status in the injured human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Anti-inflammatory drugs protect against Alzheimer disease at low doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Crude caffeine reduces memory impairment and amyloid β(1-42) levels in an Alzheimer's mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Complement receptor 1 (CR1) and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Dietary intake of antioxidants and risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Developing β-secretase inhibitors for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

TREM2 Variants in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Alzheimer's disease: the challenge of the second century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Metabolism of amyloid-beta peptide and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

The prevalence of dementia: a quantitative integration of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Assembly, trafficking and function of gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Suspected limited efficacy of γ-secretase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Editorial: The prevalence and malignancy of Alzheimer disease. A major killer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

S- but not R-enantiomers of flurbiprofen and ibuprofen reduce human microglial and THP-1 cell neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

The amyloid cascade hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Candidate gene for the chromosome 1 familial Alzheimer's disease locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Mediterranean diet, cognitive function, and dementia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Does caffeine intake protect from Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

beta-Amyloid peptide in vitro toxicity: lot-to-lot variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Activation of the classical complement pathway in brain tissue of Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Is there a future for vaccination as a treatment for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Anti-inflammatory drugs and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A decade of modeling Alzheimer's disease in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

The spectrum of disease in chronic traumatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Selective inhibition of Abeta42 production by NSAID R-enantiomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Sting of Alzheimer's failures offset by upcoming prevention trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Structure-neurotoxicity relationships of amyloid beta-protein oligomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Activation of α-secretase cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Complement activation by beta-amyloid in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Targets for AD treatment: conflicting messages from γ-secretase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

The perils of Alzheimer's drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

The molecular pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Long-term efficacy and safety of celecoxib in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Tau pathology and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Risk of Alzheimer's disease and duration of NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Protective effects of NSAIDs on the development of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Docosahexaenoic acid supplementation of primary rat hippocampal neurons attenuates the neurotoxicity induced by aggregated amyloid beta protein(42) and up-regulates cytoskeletal protein expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Cytoskeletal protein pathology and the formation of beta-amyloid fibers in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

γ-Secretase as a target for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Complement activation in very early Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1177-7

10.1007/S00401-013-1177-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 June 2017

1005348891

0 references

1 reference